CTRI/2022/06/043365进行中（未招募）3 期
A prospective, randomized, open label, activecontrolled, multicenter, phase III clinical study toevaluate the immunogenicity and safety of singlebooster dose of ZyCoV-D of M/s ZydusLifesciences Limited in adult subjects alreadyvaccinated with 2 doses of Covaxin or Covishield
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 576
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects (healthy / high risk) of either gender =18 years of age
- •2. Subjects who have received 2 doses on Covaxin or Covishield with last dose 6 (+1)
- •months prior to screening date
- •3. Informed consent from subjects
- •4. Subjects literate enough to fill the diary card
- •5. Females of childbearing potential, must agree to use one of the approved contraception methods (double barrier methods, oral or injectable hormonal contraceptives or surgical sterilization), from screening until completion of the followup visit and males who agree to use contraception
排除标准
- •1. Febrile illness (temperature = 38°C or 100.4°F) or any acute illness or infection within
- •4 weeks of enrolment
- •2. History or laboratory evidence of confirmed SARS-CoV-2 infection after primary
- •vaccination or RTPCR positive for COVID-19 at the time of screening
- •3. Subjects who have received one or two doses of any approved or experimental
- •COVID-19 vaccine other than Covaxin or Covishield in past.
- •4. History of contact with a confirmed active SARS-CoV-2 positive patient within 14 days
- •5. History of SARS/ MERS infection
- •6. Past history of hypersensitivity reaction or any serious adverse event after any
- •vaccination
- •7. Subjects with known history of thrombocytopenia or any coagulation disorder, or
- •subjects on anticoagulation therapy
- •8. Subjects with confirmed or suspected immunosuppressive or immunodeficiency
- •disorder; or subjects on any immunosuppressive or immunostimulant therapy
- •9. Clinically significant (uncontrolled) systemic disorder such as cardiovascular,
- •respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, haematological,
- •psychiatric or immunological disorder
- •10. Subjects administered blood, blood containing products or immunoglobulins within the
- •last 3 months or planned administration during the study
- •11. Any other vaccine administration within the last 30 days or planned to be administered
- •during 8 weeks after enrolment (upto day 56 of study)
- •12. Participation in another clinical trial in the past 3 months
- •13. Pregnant and lactating women
- •14. History of drug / alcohol abuse
研究者
相似试验
尚未招募
3 期
Study on effect of calcium supplementation on pregnant womeCTRI/2022/12/047860G.C Chemie Pharmie Limited
进行中（未招募）
不适用
A prospective, randomized, open-label, active-controlled study in adult subjects with acute bacterial sinusitis comparing the clinical efficacy of telithromycin (KETEK®) 800 mg once a day for 5 days versus amoxicillin-clavulanic acid (AUGMENTIN®) 875/125 mg twice a day for 10 days.acute bacterial sinusitis (ABS)MedDRA version: 7.0Level: LLTClassification code 10000858EUCTR2004-001460-42-DEAventis Intercontinental - Sanofi-aventis298
已完成
4 期
post-marketing study to evaluate the efficacy and safety of (silodosin) vs Tamsulosin in Indian male patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.CTRI/2019/12/022231Sun Pharma Industries Ltd246
已完成
不适用
Symptomatic treatment of patients suffering from productive cough associated with acute bronchitis.CTRI/2022/09/045509Dr Deepali Gaikwad60
已完成
不适用
A prospective, open label, randomized, active control, parallel design, comparative pharmacokinetics study of Intramuscular Pegaspargase (Hamsyl) of Gennova Biopharmaceuticals Ltd versus Intramuscular Oncaspar® in pediatric patients with relapsed cases of Acute Lymphoblastic Leukemia (ALL)CTRI/2016/02/006589Gennova Biopharmaceuticals Ltd29